Bruker Announces Public Offering of Common Stock
May 29 2024 - 3:14PM
Business Wire
Bruker Corporation (“Bruker” or the “Company”) (Nasdaq: BRKR)
today announced the launch of an underwritten registered public
offering of 6,000,000 shares of its common stock. In addition,
Bruker expects to grant the underwriters a 30-day option to
purchase up to an additional 900,000 shares of its common stock.
The offering is subject to market and other customary closing
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering. Bruker intends to use the net proceeds from this offering
to reduce indebtedness following its recent strategic acquisitions,
including to repay a portion of its outstanding borrowings under
the amended and restated revolving credit agreement dated as of
January 18, 2024. BofA Securities and J.P. Morgan are acting as
joint underwriters and book-running managers for the offering.
A registration statement on Form S-3 (including a preliminary
prospectus describing the terms of the offering) relating to these
securities has been filed with the Securities and Exchange
Commission (the “SEC”) and has become effective. The offering will
be made only by means of a prospectus forming a part of that
effective registration statement. A copy of the final prospectus
relating to the offering will be filed with the SEC and may be
obtained, when available, by contacting BofA Securities, Attention:
Prospectus Department, NC1-022-02-25, 201 North Tryon Street,
Charlotte, NC 28255-0001, or by email at
dg.prospectus_requests@bofa.com or J.P. Morgan, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or
by email at prospectus-eq_fi@jpmchase.com and
postsalemanualrequests@broadridge.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor is there any offer or sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Bruker Corporation – Leader of the Post-Genomic Era
(Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough
post-genomic discoveries and develop new applications that improve
the quality of human life. Bruker’s high-performance scientific
instruments and high-value analytical and diagnostic solutions
enable scientists to explore life and materials at molecular,
cellular, and microscopic levels. In close cooperation with our
customers, Bruker is enabling innovation, improved productivity,
and customer success in post-genomic life science molecular and
cell biology research, in applied and biopharma applications, in
microscopy and nanoanalysis, as well as in industrial and cleantech
research, and next-gen semiconductor metrology in support of AI.
Bruker offers differentiated, high-value life science and
diagnostics systems and solutions in preclinical imaging, clinical
phenomics research, proteomics and multiomics, spatial and
single-cell biology, functional structural and condensate biology,
as well as in clinical microbiology and molecular diagnostics. For
more information, please visit www.bruker.com.
Cautionary Statement Regarding Forward-Looking
Statements
This communication contains “forward-looking statements”
regarding the offering. All statements, other than statements of
historical fact, including statements regarding completion and
timing of the follow-on public offering and the terms of such
offering, are forward-looking in nature and are subject to risks,
uncertainties and assumptions about Bruker and its business,
including, without limitation, risks and uncertainties related to
market conditions. Such forward-looking statements involve
substantial risks and uncertainties that relate to future events
and the actual results could differ significantly from those
expressed or implied by the forward-looking statements. Any
forward-looking statements are based on Bruker’s current
expectations, estimates and assumptions regarding future events and
are applicable only as of the dates of such statements. Bruker
makes no commitment to revise or update any forward-looking
statements in order to reflect events or circumstances that may
change, except as required by law. For further discussion of these
and other risks and uncertainties, see Bruker’s most recent Form
10-K and Form 10-Q filings with the SEC. Except as required by law,
Bruker does not undertake any duty to update forward-looking
statements to reflect events after the date of this press release.
Readers are cautioned not to place undue reliance on
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240529283091/en/
Justin Ward Sr. Director, Investor Relations & Corporate
Development Bruker Corporation T: +1 (978) 313-5800 E:
Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From May 2024 to Jun 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2023 to Jun 2024